Regulatory concerns include debates about gender identity, the role of governments in health care, and the medical management of minors. Some countries restrict the use of puberty blockers, whereas others consider the drugs essential for transgender youth. The United Kingdom banned the use of puberty blockers in 2024, owing to a lack of evidence on benefits and harms.